Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of (+)-Tranylcypromine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB known ✓ | P27338 | 11/20 | 1.00 |
| ▸ | MAOA known ✓ | P21397 | 7/20 | 1.00 |
| ▸ | KDM1A | O60341 | 14/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 4/20 | 1.00 |
| ▸ | CYP2B6 | P20813 | 3/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 3/20 | 1.00 |
| ▸ | RCOR1 | Q9UKL0 | 3/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | ADRA2A | P08913 | 1/20 | 1.00 |
| ▸ | CYP2A6 | P11509 | 1/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 1.00 |
| ▸ | HTR2C | P28335 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | DRD3 | P35462 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| (+)-Tranylcypromine SCHEMBL145650 | 1.00 | KDM1A (1.00) | KDM1AMAOBMAOACYP2C19CYP2B6 | |
| (+)-Tranylcypromine SCHEMBL3406205 | 1.00 | KDM1A (1.00) | KDM1AMAOBMAOACYP2C19CYP2B6 | |
| (+)-Tranylcypromine SCHEMBL29360959 | 1.00 | KDM1A (1.00) | KDM1AMAOBMAOACYP2C19CYP2B6 | |
| (+)-Tranylcypromine SCHEMBL13764364 | 1.00 | KDM1A (1.00) | KDM1AMAOBMAOACYP2C19CYP2B6 | |
| (+)-Tranylcypromine SCHEMBL13785162 | 1.00 | KDM1A (1.00) | KDM1AMAOBMAOACYP2C19CYP2B6 | |
| (+)-Tranylcypromine SCHEMBL34339 | 1.00 | KDM1A (1.00) | KDM1AMAOBMAOACYP2C19CYP2B6 | |
| (+)-Tranylcypromine SCHEMBL1649712 | 1.00 | KDM1A (1.00) | KDM1AMAOBMAOACYP2C19CYP2B6 | |
| (+)-Tranylcypromine SCHEMBL4740285 | 1.00 | KDM1A (1.00) | KDM1AMAOBMAOACYP2C19CYP2B6 | |
| (+)-Tranylcypromine SCHEMBL40651 | 1.00 | KDM1A (1.00) | KDM1AMAOBMAOACYP2C19CYP2B6 | |
| (+)-Tranylcypromine SCHEMBL1720497 | 1.00 | KDM1A (1.00) | KDM1AMAOBMAOACYP2C19CYP2B6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3105218-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | Incyte Corporation (US) | 2016-12-21 | — | — | EP | claimed |
| WO-2015123465-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | INCYTE CORPORATION (US) | 2015-08-20 | — | — | WO | claimed |
| CN-120136884-A | Nalfurorphine Process for the preparation of intermediates | 江苏杜瑞制药有限公司 | 2025-06-13 | — | — | CN | disclosed |
| CN-117337281-A | Piperidine urea derivatives as soluble epoxide hydrolase inhibitors | 纽若平治疗公司 | 2024-01-02 | — | — | CN | disclosed |
| US-20230051773-A1 | TLR2 MODULATOR COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | AXIAL THERAPEUTICS, INC. (US) | 2023-02-16 | — | — | US | disclosed |
| US-20220025321-A1 | METHODS FOR REPROGRAMING NON-PLURIPOTENT CELLS INTO PLURIPOTENT STEM CELLS | HONG GUAN LTD. (CN) | 2022-01-27 | — | — | US | disclosed |
| WO-2021242923-A1 | TLR2 MODULATOR COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | AXIAL THERAPEUTICS, INC. (US) | 2021-12-02 | — | — | WO | disclosed |
| US-20200345700-A1 | LSD1 INHIBITOR AND PREPARATION METHOD AND APPLICATION THEREOF | MEDSHINE DISCOVERY INC. (CN) | 2020-11-05 | — | — | US | disclosed |
| US-20190282624-A1 | IMPROVED METHODS FOR REPROGRAMING NON-PLURIPOTENT CELLS INTO PLURIPOTENT STEM CELLS | BEIHAO STEM CELL AND REGENERATIVE MEDICINE RESEARCH INSTITUTE CO., LTD. (CN) | 2019-09-19 | — | — | US | disclosed |
| US-20190144499-A1 | PHENYL PROPANAMIDE DERIVATIVE, AND MANUFACTURING METHOD AND PHARMACEUTICAL APPLICATION THEREOF | JIANGSU HENGRUI MEDICINE CO., LTD. (CN) | 2019-05-16 | — | — | US | disclosed |
| US-10202330-B2 | Lysine specific demethylase-1 inhibitors and their use | ORYZON GENOMICS, SA (ES) | 2019-02-12 | — | — | US | disclosed |
| US-20110263604-A1 | Oxidase inhibitors and their use | ORYZON GENOMICS, S.A. (ES) | 2011-10-27 | — | — | US | disclosed |
| WO-2010084160-A1 | PHENYLCYCLOPROPYLAMINE DERIVATIVES AND THEIR MEDICAL USE | ORYZON GENOMICS S.A. (ES) | 2010-07-29 | — | — | WO | disclosed |
| WO-2010043721-A1 | OXIDASE INHIBITORS AND THEIR USE | ORYZON GENOMICS, S.A. (ES) | 2010-04-22 | — | — | WO | disclosed |
| EP-2177502-A1 | Compounds and their use | Oryzon Genomics, S.A. (ES) | 2010-04-21 | — | — | EP | disclosed |
| US-7273882-B2 | Aminoacetamide acyl guanidines as β-secretase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-09-25 | — | — | US | disclosed |
| US-6767910-B1 | ANTICOAGULANTS | ASTRAZENECA AB (SE) | 2004-07-27 | — | — | US | disclosed |
| EP-1216248-B1 | TRIAZOLOPYRIMIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2004-02-18 | — | — | EP | disclosed |
| EP-0996620-B1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2002-04-17 | — | — | EP | disclosed |
| US-6156756-A | Triazolo [4,5-d]pyrimidine compounds, their use as medicaments, compositions containing them and processes for their preparation | ASTRAZENECA UK LIMITED (GB) | 2000-12-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230051773-A1 | TLR2 MODULATOR COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | TLR2, TLR3, TLR4 | MAOB 3371/4885MAOA 3521/4885KDM1A 4539/4885 |
| US-20110263604-A1 | Oxidase inhibitors and their use | MAOA, PNPO, MAOB | MAOB 3/4885MAOA 1/4885KDM1A 920/4885 |
| US-20190144499-A1 | PHENYL PROPANAMIDE DERIVATIVE, AND MANUFACTURING METHOD AND PHARMACEUTICAL APPLICATION THEREOF | OPRK1, OPRD1, OPRL1 | MAOB 749/4885MAOA 594/4885KDM1A 415/4885 |
| US-20220025321-A1 | METHODS FOR REPROGRAMING NON-PLURIPOTENT CELLS INTO PLURIPOTENT STEM CELLS | AHCY, BHMT, SHMT1 | MAOB 2854/4885MAOA 2881/4885KDM1A 246/4885 |
| US-10202330-B2 | Lysine specific demethylase-1 inhibitors and their use | KDM1A, KDM1B, KDM3A | MAOB 219/4885MAOA 302/4885KDM1A 1/4885 |
| US-20200345700-A1 | LSD1 INHIBITOR AND PREPARATION METHOD AND APPLICATION THEREOF | KDM1B, KDM1A, KDM2A | MAOB 141/4885MAOA 138/4885KDM1A 2/4885 |
| US-20190282624-A1 | IMPROVED METHODS FOR REPROGRAMING NON-PLURIPOTENT CELLS INTO PLURIPOTENT STEM CELLS | AHCY, BHMT, SHMT1 | MAOB 3150/4885MAOA 3061/4885KDM1A 230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.